Key Laboratory of Protein and Peptide Pharmaceutical, National Laboratory of Biomacromolecules, CAS-University of Tokyo Joint Laboratory of Structural Virology and Immunology, Institute of Biophysics, Chinese Academy of Sciences, Beijing , China.
J Immunother. 2013 Jan;36(1):20-8. doi: 10.1097/CJI.0b013e31827810d1.
The aim of this study is to raise tumor-suppressing monoclonal antibodies (mAbs) against colorectal carcinomas. Here, we generated a novel mAb 3P9, targeted a cancer-associated carbohydrate antigen sialyl-Tn (sTn), which showed significant inhibitory effect on proliferation and migration of sTn cells and tumor growth by inducing apoptosis. We also demonstrated that mAb 3P9 showed higher sensitivity and specificity in immunohistochemistry assay on colonic adenocarcinoma than the broadly used commercial anti-sTn antibody B72.3. These results provide the first evidence that mAb 3P9 has potential applications, not only for diagnosis but also for antibody-based tumor therapy.
本研究旨在针对结直肠癌生成肿瘤抑制性单克隆抗体(mAb)。在此,我们生成了一种新型 mAb 3P9,该 mAb 针对一种癌相关碳水化合物抗原唾液酸化-Tn(sTn),通过诱导细胞凋亡,该 mAb 对 sTn 细胞的增殖和迁移以及肿瘤生长具有显著的抑制作用。我们还证明,与广泛使用的商业抗 sTn 抗体 B72.3 相比,mAb 3P9 在结直肠腺癌的免疫组织化学检测中具有更高的敏感性和特异性。这些结果首次证明 mAb 3P9 不仅具有诊断潜力,而且具有基于抗体的肿瘤治疗潜力。